Cargando…
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
BACKGROUND: In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis following treatment or not with direct antiviral agents from the...
Autores principales: | Pageaux, Georges-Philippe, Nzinga, Clovis Lusivika, Ganne, Nathalie, Samuel, Didier, Dorival, Céline, Zoulim, Fabien, Cagnot, Carole, Decaens, Thomas, Thabut, Dominique, Asselah, Tarik, Mathurin, Philippe, Habersetzer, François, Bronowicki, Jean-Pierre, Guyader, Dominique, Rosa, Isabelle, Leroy, Vincent, Chazouilleres, Olivier, de Ledinghen, Victor, Bourliere, Marc, Causse, Xavier, Cales, Paul, Metivier, Sophie, Loustaud-Ratti, Véronique, Riachi, Ghassan, Alric, Laurent, Gelu-Simeon, Moana, Minello, Anne, Gournay, Jérôme, Geist, Claire, Tran, Albert, Abergel, Armand, Portal, Isabelle, d’Alteroche, Louis, Raffi, François, Fontaine, Hélène, Carrat, Fabrice, Pol, Stanislas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796427/ https://www.ncbi.nlm.nih.gov/pubmed/35086481 http://dx.doi.org/10.1186/s12879-022-07076-0 |
Ejemplares similares
-
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
por: Laurain, Anne, et al.
Publicado: (2019) -
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017) -
Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007) -
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors
por: Carrieri, Patrizia, et al.
Publicado: (2022) -
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
por: Marcellin, Patrick, et al.
Publicado: (2016)